Sumary of Clinical trial to test personalized treatment for severe asthma caused by a specific mutation:
- Under a $10 million grant, a randomized, placebo-controlled clinical trial led by Boston Children’s Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable.
- Funded by the National Institute of Allergy and Infectious Diseases (NIAID), the four-center trial follows a half-decade of research at the hospital showing how a mutation in the gene ILR4 causes severe, hard-to-treat asthma — and the potential for an existing drug to counter it.
- The trial, called Investigating Dupilumab’s Effect in Asthma by Genotype (IDEA), will test a monoclonal antibody, dupilumab (Dupixent®), in 150 patients age 12 and older with and without the ILR4 mutation.
- There are a lot of disparities in asthma severity, so in this study we hope to help inner-city disadvantaged kids who disproportionately are affected by this genotype.
- ” Wanda Phipatanakul, MD, Trial Principal Investigator, Division of Immunology, Boston Children’s ILR4 encodes the cellular receptor for IL-4, a cytokine (chemical messenger) that plays a key role in inflammation.
- Duplimab blocks the same receptor, and the researchers hope it will also curb inflammatory responses in asthma.
- The drug is already FDA-approved for the treatment of asthma in adults and eczema in children.